Clinical trials: Cancer of the Head and Neck
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
This clinical trial tests the impact of offering hearing tests (audiometry) close to home and remotely on participation in monitoring for treatment-related hearing loss in patients with head and neck squamous cell cancer…
- Conditions
- Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06662058
- Testing
- Audiometric Test, Interview
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- Emory University
Squamous Cell Carcinoma of Head and Neck
Concurent Chemoradiotherapy in Head and Neck Cancers
To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\m2) for…
- Trial name
- NCT04780750
- Testing
- Docetaxel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Head and Neck Fibrosis
PentoxIfylline and Tocopherol for the Treatment of Post-radiotherapy Fibrosis in Head and Neck Cancer Patients
Objectives: This is a feasibility study in preparation for the main multicentre randomised trial, which is anticipated to have two arms: Arm A: the current best standard of care [rehabilitation exercises] Arm B: the current best…
- Trial name
- PITSTOP (NCT03723291)
- Testing
- Arm B: A combination of pentoxifylline and tocopherol acetate in addition to best standard care [a structured programme of rehabilitation exercises] for 6 months, • Arm A: Best standard of care only [a structured programme of rehabilitation exercises] for 6 months
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College, London
Tongue Cancer, Squamous Cell Carcinoma
Surgical Margin Assessment by 3D Ultrasound
Complete removal of cancer encircled by a secure margin of healthy tissue is the aim of surgical oncology. A close or positive surgical margin reported by pathologist typically ends in adjuvant therapies (re-surgery and/or…
- Conditions
- Tongue Cancer, Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT05740774
- Testing
- 3D ultrasound
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Head and Neck Cancer
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
The purpose of this study is to find out whether adding ZD1839 to standard treatment (Cisplatin and Radiation Therapy) of unresectable head and neck cancers is better than cisplatin and radiation alone.
- Trial name
- NCT00195078
- Testing
- ZD1839 (IRESSA), Cisplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Weill Medical College of Cornell University
Head and Neck Cancer (H&N)
Screening Psychosocial Distress in Head and Neck Cancer
This prospective, multicenter study aims to assess the presence of psychosocial distress using the Distress Thermometer in patients treated for head and neck cancer at the initiation of their speech-language therapy.
- Trial name
- DEP-VADS-ORTHO (NCT07851818)
- Testing
- Psychosocial distress screening using the Distress Thermometer
- Volunteers
- 80 people
- Sponsor
- Hôpital NOVO
Squamous Cell Carcinoma of the Head and Neck
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck
A small group of skin cancers of the head and neck, called resected cutaneous squamous carcinomas, are more aggressive than most cancers of this type, even after being treated with standard therapy.
- Trial name
- NCT03057613
- Testing
- Pembrolizumab, IMRT 60-66Gy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
A multi-center, open, randomized controlled, phase II clinical study to evaluate the efficiency and safety of chemotherapy and immunotherapy combined with locol radiotharepy in treatment of patients with oligometastatic…
- Trial name
- NCT05183958
- Testing
- Radiotherapy group, Camrelizumab, Chemotherapy
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Zhejiang Cancer Hospital
Oral Mucositis
A Study to Describe the Effect of Photobiomodulation (Low Level Laser Therapy) in Reducing the Severity and Incidence of Oral Mucositis (Oral Ulceration) in Oral Cancer Patients Undergoing Radiation Treatment
The goal of this study is to describe the effect of photobiomodulation (PBM) on the incidence and severity of oral mucositis in post-operative oral cancer patients receiving radiotherapy +/- chemotherapy.
- Trial name
- PBM (NCT07387978)
- Testing
- photobiomodulation
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer
- Trial name
- NCT00002947
- Testing
- indium In 111 pentetreotide
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Yale University
Oropharynx Cancer
Staying Connected: a Mobile Health Study With the Noona® and Mobili-T® Systems
Mobile health applications are an attractive technological solution that facilitates access to care for patients conveniently and efficiently.
- Trial name
- NCT05368025
- Testing
- Mobili-T/Noona
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- University of Alberta
Thyroid Cancer
Proteogenomics for Follicular Cell-derived Thyroid Cancer: Development of a Classification and Prognosis Prediction Model
This study aims to refine the molecular classification of thyroid cancer (TC) using a multi-omics approach. By identifying a novel gene set and applying decision-tree modeling, the study seeks to improve diagnostic accuracy and…
- Trial name
- NCT06969768
- Where
- South Korea
- Volunteers
- 275 people
- Sponsor
- Seoul National University Hospital
Head and Neck Cancer, Esophageal Cancer
Plasma Circulating Deoxyribonucelic Acid (DNA) as a Response Marker
This study investigates whether the amount of circulating plasma DNA can be used as a response marker for anti-cancer treatment in treating gross tumors.
- Trial name
- NCT00318604
- Sponsor
- Far Eastern Memorial Hospital
Cancer of the Head and Neck
Effects of Expiratory Muscle Strength Training on Airway Protection and Swallowing in Chronic Dysphagia After Radiation Therapy
Radiation therapy for head and neck cancer (HNC) is associated with the development of swallowing difficulties, or dysphagia. Dysphagia has profound negative effects on the health, nutritional status, and quality of life of HNC…
- Trial name
- NCT03620084
- Testing
- Expiratory Muscle Strength Training (EMST)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore General Hospital
Lung Cancer, Liver Cancer
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
This trial is designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by infusion of CTLA4, PD1 and PDL1 antibodies combination through venous (IV), artery (IA) or…
- Conditions
- Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT05187338
- Testing
- ipilimumab +pembrolizumab +durvalumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Mucositis, Xerostomia
Effectiveness of Photobiomodulation Protocols in Radiation-induced Oral Side Effects in H&N Cancer Patients
Head and neck cancer (HNC) are among the most frequent malignancies in the world. The main treatment modalities for HNC are surgical excision, radiotherapy (RT), and chemotherapy (CT).
- Conditions
- Mucositis, Xerostomia, Hyposalivation
- Trial name
- NCT05242991
- Testing
- Photobiomodulation therapy
- Where
- Brazil
- Volunteers
- 132 people
- Sponsor
- Federal University of Rio Grande do Sul
Head and Neck Neoplasm, Radiotherapy
Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients
Treated head and neck cancer patients are subject to tissue swelling and scarring, known as lymphedema and fibrosis (LEF). LEF in the head and neck cancer patient occurs in up to 90% of treated patients and is associated with…
- Trial name
- NCT04679233
- Testing
- Prescription aerobic exercise
- Where
- United States
- Sponsor
- Vanderbilt University
Nasopharyngeal Carcinoma
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
The purpose of this study is to verify the role of adding cisplatin chemotherapy to the intensity-modulated radiotherapy (IMRT) for stage II nasopharyngeal carcinoma.
- Trial name
- NCT01187238
- Testing
- cisplatin
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- Chinese Academy of Medical Sciences
Esophageal Fistula, Esophageal Neoplasms
Removal of the Evolution® Esophageal Stent - Fully Covered
The CLARITY study is a clinical trial approved by US FDA to study the removal of the Evolution® Esophageal Stent-Fully Covered in malignant and benign indications.
- Conditions
- Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Esophageal Stenosis
- Trial name
- CLARITY (NCT01900691)
- Testing
- Evolution® Esophageal Stent - Fully Covered
- Where
- 11 sites in United States
- Volunteers
- 130 people
- Sponsor
- Cook Group Incorporated
Head and Neck Cancer
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
The goal of this clinical research study is to learn if giving the new drug, Tarceva® (OSI-774), in combination with Platinol® (cisplatin) and Taxotere® (docetaxel) is effective in the treatment of metastatic or recurrent head…
- Trial name
- NCT00076310
- Testing
- Docetaxel, OSI-774, Cisplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.